Access the full text.
Sign up today, get DeepDyve free for 14 days.
Ohman Ohman, Kleiman Kleiman, Gacioch Gacioch (1997)
Combined accelerated tissue‐plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with integrilin in acute myocardial infarction: Results of a randomized, placebo‐controlled, dose‐ranging trialCirculation, 95
E. Veys, A. Govaerts, E. Coigne, H. Mielants, A. Verbruggen (1974)
HL-A AND INFECTIVE SACROILEITISThe Lancet, 304
C. Hamm, C. Heeschen, B. Goldmann, A. Vahanian, J. Adgey, C. Miguel, W. Rutsch, J. Berger, J. Kootstra, M. Simoons (1999)
Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators.The New England journal of medicine, 340 21
Gusto Investigators (1993)
The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction.The New England journal of medicine, 329 22
E. Antman, R. Giugliano, C. Gibson, C. Mccabe, P. Coussement, N. Kleiman, A. Vahanian, A. Adgey, I. Menown, H. Rupprecht, R. Wieken, J. Ducas, J. Scherer, K. Anderson, F. Werf, E. Braunwald (1999)
Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators.Circulation, 99 21
Ohman Ohman, Califf Califf, Topol Topol (1990)
Consequences of re‐occlusion after successful reperfusion therapy in acute myocardial infarctionCirculation, 82
Julie Miller, Richard Smalling, E. Ohman, Christoph Bode, A. Betriu, Neal Kleiman, Jonathan Schildcrout, Eugenia Bastos, E. Topol, R. Califf (1999)
Effectiveness of early coronary angioplasty and abciximab for failed thrombolysis (reteplase or alteplase) during acute myocardial infarction (results from the GUSTO-III trial). Global Use of Strategies To Open occluded coronary arteries.The American journal of cardiology, 84 7
J. Wilentz, T. Sanborn, C. Haudenschild, C. Valeri, T. Ryan, D. Faxon (1987)
Platelet accumulation in experimental angioplasty: time course and relation to vascular injury.Circulation, 75 3
Harker Harker, Ritchie Ritchie (1980)
The role of platelets in acute vascular eventsCirculation, 62
E. Topol (1998)
Toward a new frontier in myocardial reperfusion therapy: emerging platelet preeminence.Circulation, 97 2
A. Lincoff, E. Topol (1993)
Illusion of Reperfusion Does Anyone Achieve Optimal Reperfusion During Acute Myocardial Infarction?Circulation, 87
Stone Stone, Grines Grines, Cox Cox (2000)
A prospective, randomized trial comparing primary balloon angioplasty with or without abciximab to primary stenting with or without abciximab in acute myocardial infarction—Primary endpoint analysis from the Cadillac TrialCirculation, 102
Ronner Ronner, Wieken Wieken, Salgboom Salgboom (2000)
IIb/IIIa receptor antagonists for failed rescue angioplastyCirculation, 101
H. Gold, H. Garabedian, R. Dinsmore, L. Guerrero, J. Cigarroa, I. Palacios, R. Leinbach (1997)
Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators. Observations in animals and humans.Circulation, 95 7
B. Coller (1990)
Platelets and thrombolytic therapy.The New England journal of medicine, 322 1
R. Califf, E. Topol, B. George, Jane Boswick, Kerry Lee, D. Stump, J. Dillon, C. Abbottsmith, R. Candela, D. Kereiakes, W. O’Neill, R. Stack (1988)
Characteristics and outcome of patients in whom reperfusion with intravenous tissue-type plasminogen activator fails: results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) I trial.Circulation, 77 5
InTIME-II Investigators (2000)
Intravenous NPA for the treatment of infarcting myocardium early; InTIME-II, a double-blind comparison of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction.European heart journal, 21 24
E. Ronner, L. Wieken, T. Slagboom, G. Laarman, F. Kiemeneij (2000)
Images in cardiovascular medicine. IIb/IIIa receptor antagonists for failed rescue angioplasty.Circulation, 101 2
D. Sundlof, P. Rerkpattanapitat, N. Wongpraparut, P. Pathi, M. Kotler, L. Jacobs, G. Ledley, S. Yazdanfar (1999)
Incidence of bleeding complications associated with abciximab use in conjunction with thrombolytic therapy in patients requiring percutaneous transluminal coronary angioplasty.The American journal of cardiology, 83 11
F. Zijlstra, M. Boer, J. Hoorntje, S. Reiffers, J. Reiber, H. Suryapranata (1993)
A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction.The New England journal of medicine, 328 10
P. Jong, E. Cohen, W. Batchelor, C. Lazzam, C. Kreatsoulas, M. Natarajan, B. Strauss (2001)
Bleeding risks with abciximab after full-dose thrombolysis in rescue or urgent angioplasty for acute myocardial infarction.American heart journal, 141 2
C. Grines, K. Browne, J. Marco, D. Rothbaum, G. Stone, J. O'Keefe, P. Overlie, B. Donohue, N. Chelliah, G. Timmis, R. Vlietstra, M. Strzelecki, S. Puchrowicz-Ochocki, W. O’Neill (1993)
A Comparison of Immediate Angioplasty with Thrombolytic Therapy for Acute Myocardial InfarctionThe New England Journal of Medicine, 328
J. O'Keefe, B. Rutherford, D. Mcconahay, R. Ligon, W. Johnson, L. Giorgi, J. Crockett, B. Mccallister, R. Conn, G. Gura, T. Good, D. Steinhaus, T. Bateman, T. Shimshak, G. Hartzler (1989)
Early and late results of coronary angioplasty without antecedent thrombolytic therapy for acute myocardial infarction.The American journal of cardiology, 64 19
Ross Ross, Lundergan Lundergan, Rohrbeck Rohrbeck (1998)
Rescue angioplasty after failed thrombolysis and clinical outcomes in a large thrombolysis trialJ Am Coll Cardiol, 31
M. Simoons, P. Serruys, M. brand, J. Res, F. Verheugt, X. Krauss, W. Remme, F. Bär, C. Zwaan, A. Laarse, F. Vermeer, J. Lubsen (1986)
Early thrombolysis in acute myocardial infarction: limitation of infarct size and improved survival.Journal of the American College of Cardiology, 7 4
M. Gawaz, Franz‐Josef Neumann, I. Ott, A. May, Silja Rüdiger, A. Schömig (1996)
Changes in membrane glycoproteins of circulating platelets after coronary stent implantation.Heart, 76
F. Vermeer, A. Ophuis, E Berg, L. Brunninkhuis, C. Werter, A. Boehmer, A. Lousberg, W. Dassen, F. Bar (1999)
Prospective randomised comparison between thrombolysis, rescue PTCA, and primary PTCA in patients with extensive myocardial infarction admitted to a hospital without PTCA facilities: a safety and feasibility studyHeart, 82
F. Werf (1999)
Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trialThe Lancet, 354
Am J Cardiol, 74
K. Koch, J. Dahl, E. Kleinhans, Heinrich Klues, P. Radke, Susanne Ninnemann, G. Schulz, U. Buell, P. Hanrath (1999)
Influence of a platelet GPIIb/IIIa receptor antagonist on myocardial hypoperfusion during rotational atherectomy as assessed by myocardial Tc-99m sestamibi scintigraphy.Journal of the American College of Cardiology, 33 4
Circulation, 101
Antman Antman, Giugliano Giugliano, Gibson Gibson (1999)
For the TIMI‐14 Investigators. Abciximab facilitates the rate and extent of thrombolysis: Results of the Thrombolysis In Myocardial Infarction 14 TrialCirculation, 99
T. Investigators (1997)
Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis.Circulation, 96 5
P. Pasquale, F. Sarullo, S. Cannizzaro, M. Vitrano, B. Vincenzo, F. Giambanco, A. Scandurra, G. Calcaterra, S. Paterna (2001)
Effects of Administration of Glycoprotein IIb/IIIa Receptor Antagonists in Patients with Failed ThrombolysisClinical Drug Investigation, 21
J. Lemos, E. Antman, C. Gibson, C. Mccabe, R. Giugliano, S. Murphy, S. Coulter, K. Anderson, J. Scherer, M. Frey, R. Wieken, F. Werf, E. Braunwald (2000)
Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial.Circulation, 101 3
Christoph Bode, R. Smalling, Gunther Berg, Curtis Burnett, Gerald Lorch, John Kalbfleisch, Robert Chernoff, Leonard Christie, Robert Feldman, A. Seals, W. Weaver (1996)
Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. The RAPID II Investigators.Circulation, 94 5
Stephen Ellis, E. Silva, C. Spaulding, M. Nobuyoshi, B. Weiner, J. Talley (2000)
Review of immediate angioplasty after fibrinolytic therapy for acute myocardial infarction: insights from the RESCUE I, RESCUE II, and other contemporary clinical experiences.American heart journal, 139 6
Hamm Hamm, Heeschen Heeschen, Goldmann Goldmann (1999)
Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levelsN Engl J Med, 340
Franz‐Josef Neumann, A. Kastrati, C. Schmitt, R. Blasini, M. Hadamitzky, J. Mehilli, M. Gawaz, M. Schleef, M. Seyfarth, J. Dirschinger, A. Schömig (2000)
Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction.Journal of the American College of Cardiology, 35 4
A. Ross, C. Lundergan, S. Rohrbeck, D. Boyle, M. Brand, C. Buller, D. Holmes, J. Reiner (1998)
Rescue angioplasty after failed thrombolysis: technical and clinical outcomes in a large thrombolysis trial. GUSTO-1 Angiographic Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.Journal of the American College of Cardiology, 31 7
Paula Miller, Bruce Brodie, Bruce Brodie, R. Weintraub, R. Weintraub, E. LeBauer, E. LeBauer, J. Katz, J. Katz, T. Stuckey, T. Stuckey, C. Hansen, C. Hansen (1987)
Emergency coronary angioplasty for acute myocardial infarction. Results from a community hospital.Archives of internal medicine, 147 9
Wilentz Wilentz (1987)
Sanborn TA, Haudenschild CC, et al. Platelet accumulation in experimental angioplasty: Time course in relation to cardiovascular injuryCirculation, 75
Epic Investigators (1994)
Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty.The New England journal of medicine, 330 14
V. Fuster, L. Badimón, J. Badimón, J. Chesebro (1992)
The pathogenesis of coronary artery disease and the acute coronary syndromes (2).The New England journal of medicine, 326 5
H. Dauerman, C. Andreou, M. Perras, Joy Spinner, D. Lessard, B. Weiner (2000)
Predictors of Bleeding Complications After Rescue Coronary InterventionsJournal of Thrombosis and Thrombolysis, 10
Circulation, 96
J. Lefkovits, R. Ivanhoe, R. Califf, B. Bergelson, K. Anderson, Gail Stoner, H. Weisman, E. Topol (1996)
Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. EPIC investigators.The American journal of cardiology, 77 12
E. Ronner, H. Kesteren, P. Zijnen, U. Tebbe, P. Molhoek, C. Cuffie, E. Veltn, T. Lorenz, K. Neuhaus, M. Simoons (1998)
Combined Therapy With Streptokinase and IntegrilinJournal of the American College of Cardiology, 31
J Am Coll Cardiol, 12
W. Cantor, A. Kaplan, J. Velianou, M. Sketch, G. Barsness, P. Berger, E. Ohman (2001)
Effectiveness and safety of abciximab after failed thrombolytic therapy.The American journal of cardiology, 87 4
E. Ohman, R. Califf, E. Topol, R. Candela, C. Abbottsmith, Stephen Ellis, K. Sigmon, D. Kereiakes, B. George, R. Stack (1990)
Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group.Circulation, 82 3
Eur Heart J, 21
Franz‐Josef Neumann, R. Blasini, C. Schmitt, E. Alt, J. Dirschinger, M. Gawaz, A. Kastrati, A. Schömig (1998)
Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction.Circulation, 98 24
D. Rawitscher, T. Levin, I. Cohen, T. Feldman (1997)
Rapid reversal of no-reflow using Abciximab after coronary device intervention.Catheterization and cardiovascular diagnosis, 42 2
E. Ohman, N. Kleiman, G. Gacioch, S. Worley, F. Navetta, J. Talley, Anderson Hv, Stephen Ellis, Cohen, D. Spriggs, Michael Miller, D. Kereiakes, S. Yakubov, M. Kitt, K. Sigmon, Califf Rm, Mitchell Krucoff, Topol Ej (1997)
Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators.Circulation, 95 4
G. Montalescot, P. Barragan, O. Wittenberg, P. Ecollan, S. Elhadad, Ph Villain, Jean-Marc Boulenc, M. Morice, L. Maillard, M. Pansieri, R. Choussat, P. Pinton (2001)
Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction.The New England journal of medicine, 344 25
L. Merkhof, F. Zijlstra, H. Olsson, L. Grip, G. Veen, F. Bär, M. Brand, M. Simoons, F. Verheugt (1999)
Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty. Results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) pilot study.Journal of the American College of Cardiology, 33 6
Neal Kleiman, E. Ohman, Califf Rm, Barry George, D. Kereiakes, F. Aguirre, H. Weisman, Thomas Schaible, E. Topol (1993)
Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study.Journal of the American College of Cardiology, 22 2
Di Pasquale Di Pasquale, Sarullo Sarullo, Cannizzaro Cannizzaro (2001)
Effects of the administration of GP IIb/IIIa receptor antagonists in patients with failed thrombolysis: A pilot studyClin Drug Invest, 21
Qasim Qasim, Chauhan Chauhan, More More (2000)
Failed thrombolysisInt J Cardiol, 75
Stephen Ellis, Expedito Silva, G. Heyndrickx, J. Talley, C. Cernigliaro, G. Steg, C. Spaulding, M. Nobuyoshi, R. Erbel, C. Vassanelli, E. Topol (1994)
Randomized comparison of rescue angioplasty with conservative management of patients with early failure of thrombolysis for acute anterior myocardial infarction.Circulation, 90 5
I. Belenkie, M. Traboulsi, Hall Ca, Hansen Jl, Roth Dl, D. Manyari, Filipchuck Ng, Schnurr Lp, Rosenal Tw, Eldon Smith (1992)
Rescue angioplasty during myocardial infarction has a beneficial effect on mortality: a tenable hypothesis.The Canadian journal of cardiology, 8 4
D. Rothbaum, T. Linnemeier, R. Landin, E. Steinmetz, J. Hillis, C. Hallam, R. Noble, Martin See (1987)
Emergency percutaneous transluminal coronary angioplasty in acute myocardial infarction: a 3 year experience.Journal of the American College of Cardiology, 10 2
Lancet, 1
Bode Bode, Smalling Smalling, Berg Berg (1996)
Coronary heart disease/atherosclerosis/myocardial infarction: Randomized comparison of coronary thrombolysis achieved with double‐bolus reteplase (recombinant plasminogen activator) and front‐loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarctionCirculation, 94
Moliterno Moliterno, Harrington Harrington, Krukoff Krukoff (1996)
More complete and stable reperfusion with platelet IIb/IIIa antagonism plus thrombolysis for AMI: The PARADIGM trial, (abstract)Circulation, 94
S. Brener, L. Barr, J. Burchenal, S. Katz, B. George, A. Jones, E. Cohen, Phillip Gainey, H. White, H. Cheek, J. Moses, D. Moliterno, M. Effron, E. Topol (1998)
Randomized, Placebo-Controlled Trial of Platelet Glycoprotein IIb/IIIa Blockade With Primary Angioplasty for Acute Myocardial InfarctionCirculation, 98
A. Qasim, A. Chauhan, R. More (2000)
Failed thrombolysis in myocardial infarction.International journal of cardiology, 75 1
A. Lincoff, A. Lincoff, E. Topol, E. Topol, R. Califf, R. Califf, K. Sigmon, K. Sigmon, Kerry Lee, Kerry Lee, E. Ohman, E. Ohman, U. Rosenschein, U. Rosenschein, Stephen Ellis, Stephen Ellis (1995)
Significance of a coronary artery with thrombolysis in myocardial infarction grade 2 flow "patency" (outcome in the thrombolysis and angioplasty in myocardial infarction trials). Thrombolysis and Angioplasty in Myocardial Infarction Study Group.The American journal of cardiology, 75 14
M. Gawaz, Franz‐Josef Neumann, I. Ott, Alexander Schiessler, A. Schömig (1996)
Platelet function in acute myocardial infarction treated with direct angioplasty.Circulation, 93 2
Ronner Ronner, Kesteren Kesteren, Zinjen Zinjen (1998)
Combined therapy with streptokinase and integrilin (abstract)J Am Coll Cardiol, 31
C. Davies, O. Ormerod (1998)
Failed coronary thrombolysisThe Lancet, 351
It is clear that survival and better outcomes after acute myocardial infarction (AMI) are dependent on rapid, complete, and sustained reperfusion of the affected myocardium. Thrombolytic therapy is currently the most common reperfusion strategy in AMI, however, a significant proportion of patients fail to reach reperfusion with this form of therapy. There is evidence from randomized trials that rescue percutaneous coronary intervention (PCI) for failed thrombolysis may convey better outcomes to patients when compared to a conservative management. Nevertheless, it is not surprising that in this inherently thrombogenic milieu, rescue PCI has a lower success rate and a high incidence of rethrombosis, which have a profoundly negative impact on the outcome of patients. Platelets are thought to play a central role in the pathophysiology of failed thrombolysis and in the thrombotic complications following PCIs. Therefore, platelet glycoprotein (GP) IIb/IIIa antagonist may be of benefit in the setting of rescue PCI. Two retrospective subgroup analyses have suggested that these potent antiplatelet agents may improve the outcome of patients undergoing rescue PCI after failed full‐dose thrombolytic therapy. An increase in major bleeding, however, has also been noted. Therefore, in light of the lack of evidence deriving from randomized, placebo‐controlled trials, careful consideration of several aspects relevant to this setting is needed before GP IIb/IIIa antagonists are administered in rescue percutaneous coronary procedures.
Journal of Interventional Cardiology – Wiley
Published: Apr 1, 2002
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.